<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479205</url>
  </required_header>
  <id_info>
    <org_study_id>FRAITASIT</org_study_id>
    <nct_id>NCT01479205</nct_id>
  </id_info>
  <brief_title>Induction of Allergen Specific Bronchial Immunotolerance After Specific Immunotherapy</brief_title>
  <acronym>ITASIT</acronym>
  <official_title>Security of the Bronchial Allergen Provocation With Mite and Aspergillus and Predictors for a Positive Reaction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One aim of this study was to find out if the bronchial allergen provocation (BAP) is an
      appropriate method to appraise the efficacy of a specific immunotherapy (SIT). The
      investigators had one group of children receiving SIT and one group of patients who denied a
      SIT although they had an indication for it. Retrospectively the investigators analysed the
      data of the first BAP and blood parameters specific IgE-mite, total IgE before SIT (November
      2008 till February 2010). Prospectively The investigators analysed the lung parameters and
      allergic labor parameters that we got in the course of the second BAP. The investigators mean
      parameter was PD20FEV1-mite. Another aim of The investigators study was to find specific
      immunological differences between children who improved because of SIT and those who showed
      no improvement. Thus, The investigators compared the levels of total IgE, cumulative IgE-mite
      and specific IgE-mite before and after SIT and the levels of specific IgG-mite and specific
      IgG4-mite after SIT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One aim of this study was to find out if the bronchial allergen provocation(BAP) is an
      appropriate method to appraise the efficacy of a specific immunotherapy (SIT). We had one
      group of children receiving SIT and one group of patients who denied a SIT although they had
      an indication for it. Retrospectively we analysed the data of the first BAP (PD20FEV1, VC,
      FEV1, FEV1/VC (%), eNO) and allergic blood parameters like specific IgE-mite, total IgE,
      cumulative IgE before SIT (November 2008 till February 2010). Prospectively we analysed the
      lung parameters and allergic labor parameters that we got in the course of the second BAP.
      Our mean parameter was PD20FEV1-mite. Another aim of our study was to find specific
      immunological differences between children who improved because of SIT and those who showed
      no improvement. Thus, we compared the levels of total IgE, cumulative IgE-mite and specific
      IgE-mite before and after SIT and the levels of specific IgG-mite and specific IgG4-mite
      after SIT. Additionally all patients answered a questionnaire according to ISAAC about their
      clinical symptoms, their quality of life and their medication score.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in BAP</measure>
    <time_frame>one year after initiation of SIT</time_frame>
    <description>significant improvement of PD20FEV1-mite in BAP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life and medication</measure>
    <time_frame>1 year after initiation of SIT</time_frame>
    <description>Via questionnaire (adapted from ISAAC-study) we assessed the quality of life, clinical symptoms and medication scores of the patients included</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Mite Allergy</condition>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>mite allergic patients without SIT</arm_group_label>
    <description>patients suffering from allergic asthma/ rhino-conjunctivitis denying specific immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mite allergic patients with SIT</arm_group_label>
    <description>patients suffering from allergic asthma/ rhino-conjunctivitis undergoing mite specific immunotherapy</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children aged 6-17 years of age with house dust mite allergy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  between 5 and 18 years of age

          -  diagnosis of a moderate Asthma bronchiale (I-II) in the last 12 months or rhino
             conjunctivitis

          -  no exacerbation &gt; 4 weeks before Visit

        Exclusion Criteria:

          -  age &lt; 5 years &gt; 18 years,

          -  FEV1 &lt; 75%

          -  no cooperation to undergo the BAP,

          -  exacerbation within the last 28 days before Visit

          -  other serious illnesses

          -  taking part in other clinical trials &lt; 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zielen, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Paediatric Allergy and Pulmonology</name>
      <address>
        <city>Frankfurt (Main)</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD001186. doi: 10.1002/14651858.CD001186.pub2. Review.</citation>
    <PMID>20687065</PMID>
  </reference>
  <reference>
    <citation>Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy. 2010 Dec;65(12):1614-21. doi: 10.1111/j.1398-9995.2010.02413.x.</citation>
    <PMID>20645937</PMID>
  </reference>
  <reference>
    <citation>Blumberga G, Groes L, Dahl R. SQ-standardized house dust mite immunotherapy as an immunomodulatory treatment in patients with asthma. Allergy. 2011 Feb;66(2):178-85. doi: 10.1111/j.1398-9995.2010.02451.x. Epub 2010 Sep 30.</citation>
    <PMID>20883456</PMID>
  </reference>
  <reference>
    <citation>Schulze J, Rosewich M, Dressler M, Riemer C, Rose MA, Zielen S. Bronchial allergen challenge using the Medicaid dosimeter. Int Arch Allergy Immunol. 2012;157(1):89-97. doi: 10.1159/000324473. Epub 2011 Sep 7.</citation>
    <PMID>21912178</PMID>
  </reference>
  <results_reference>
    <citation>Zielen S, Christmann M, Kloska M, Dogan-Yildiz G, Lieb A, Rosewich M, Schubert R, Rose MA, Schulze J. Predicting short term response to anti-inflammatory therapy in young children with asthma. Curr Med Res Opin. 2010 Feb;26(2):483-92. doi: 10.1185/03007990903485148.</citation>
    <PMID>20001651</PMID>
  </results_reference>
  <results_reference>
    <citation>Schubert R, Eickmeier O, Garn H, Baer PC, Mueller T, Schulze J, Rose MA, Rosewich M, Renz H, Zielen S. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148(3):251-60. doi: 10.1159/000161585. Epub 2008 Oct 10.</citation>
    <PMID>18849616</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosewich M, Schulze J, Eickmeier O, Telles T, Rose MA, Schubert R, Zielen S. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol. 2010 Jun;160(3):403-10. doi: 10.1111/j.1365-2249.2010.04106.x. Epub 2010 Mar 16.</citation>
    <PMID>20345983</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 22, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2011</study_first_posted>
  <last_update_submitted>November 23, 2011</last_update_submitted>
  <last_update_submitted_qc>November 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Stefan Zielen</investigator_full_name>
    <investigator_title>Prof. Dr. med Stefan Zieln</investigator_title>
  </responsible_party>
  <keyword>specific immunotherapy</keyword>
  <keyword>bronchial allergen provocation</keyword>
  <keyword>specific IgE</keyword>
  <keyword>specific IgG</keyword>
  <keyword>specific IgG4</keyword>
  <keyword>SIT</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

